#United States #INOVIO #DNA medicines #Plymouth Meeting #HPV

INOVIO Advances DNA Medicine Discussion at National Conferences

INOVIO Pharmaceuticals, a trailblazer in the biotechnology sector, will be making its mark at two prominent scientific conferences this month. As a company dedicated to pioneering DNA medicines capable of treating various diseases, including HPV-related ailments and certain cancers, INOVIO’s participation reinforces its commitment to research and innovation.

Upcoming Conference Appearances

American Society of Gene and Cell Therapy Annual Meeting

Location: Boston
Date: May 12, 2026
Time: 5:00 - 6:30 PM ET
Presentation: A poster titled "Bleeding phenotype correction in hemophilia A mice following in vivo Factor VIII gene transfer by electroporation in skeletal muscle cells" will be showcased. This research explores potential advancements in hemophilia treatment through novel gene therapies.

American Society of Clinical Oncology Annual Meeting

Location: Chicago
Date: May 30, 2026
Time: 1:30 - 4:30 PM CDT
Presentation: INOVIO will present a poster on the study titled "B cell responses in Recurrent Respiratory Papillomatosis patients treated with DNA immunotherapy INO-3107." This study underlines the promising effects of DNA immunotherapy in combating viral infections associated with recurrent respiratory papillomatosis, a rare but serious condition caused by HPV.

Following these presentations, INOVIO plans to share the available abstracts through its official website, ensuring that stakeholders and interested parties can access the latest findings and advancements in DNA medicine.

About INOVIO

INOVIO stands at the forefront of biopharmaceutical innovation, devoted to the research, development, and commercialization of DNA medicines. These pharmaceuticals are designed to instruct the body to produce its own tools for combating diseases, promoting a revolutionary approach in treating conditions such as HPV-related diseases and various cancers. As part of its mission, INOVIO prioritizes enhancing the design and delivery of its DNA-based therapeutics to maximize their efficacy.

The biotechnology industry's growth and value are reflective of the increasing need for advanced therapeutic options, particularly as global health challenges evolve. With initiatives positioned at the forefront of biotechnology, INOVIO not only contributes significantly to the scientific community but also plays a crucial role in public health improvements.

For those seeking more detailed information about INOVIO's pioneering projects and breakthrough studies, please visit their website at www.inovio.com.

Conclusion

As INOVIO prepares to engage with fellow researchers and industry leaders at these significant gatherings, the outcomes of their presentations could hold transformative potential for patients suffering from challenging diseases. The results may significantly contribute to shaping future treatment paradigms and furthering our understanding of DNA medicine's capabilities in modern healthcare.

For media inquiries related to INOVIO’s participation and additional information storage, please contact Jennie Willson at (267) 429-8567 or reach out to Peter Vozzo for investor relations at ICR Healthcare via (443) 213-0505. The impact of INOVIO’s work is not to be taken lightly, as they pave the way forward in innovative treatment solutions.